News

The FDA has granted traditional approval for Tibotec Therapeutics’ Intelence (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Intelence is currently marketed in the US by Tibotec, a

Sinovac Biotech has executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd (Sinovac Dalian). The JV will research, develop, produce and commercialise human-use

Idera Pharmaceuticals and Merck & Co., have extended its research collaboration for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration

Idera Pharmaceuticals has announced that Novartis will terminate its research collaboration agreement with the company, effective as of February 21, 2010. Sudhir Agrawal, chief executive officer and chief

Human Genome Sciences has submitted a Biologics License Application (BLA) to the FDA for Zalbin (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes

UK-based Synexus has recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited in excess of two thousand

Accovion supports CSL Behring in successfully obtaining marketing authorisation for Berinert Berinert, a human C1 esterase inhibitor (C1-INH) for treating acute episodes of facial or abdominal hereditary angioedema

Biovitrum has completed the first of two clinical phase II studies, designed to together show proof of concept of Kiobrina (rhBSSL) in preterm infants. The results show statistically

Ipsen has initiated an international, multi-center, controlled, randomised Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational steroid sulfatase (STS) inhibitor, in advanced